Arvinas (ARVN) received early approval of Vepdeg ahead of its June 5, 2026 PDUFA date, marking both the company’s first approval and the first PROTAC degrader approved in breast cancer, though commercialization remains uncertain without a disclosed partner, Truist tells investors in a research note. The firm has a Hold rating and $10 price target on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas trading resumes
- Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
- Arvinas trading halted, news pending
- Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
- Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating